New biosensor aims to improve glucose control for type 1 diabetes patients

NCT ID NCT04081883

Completed Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested a new biosensor designed to measure blood glucose every 10 minutes in people with type 1 diabetes who use an insulin pump. The sensor uses microdialysis to sample interstitial fluid and was compared to standard continuous glucose monitors (CGM) during daily activities like meals and exercise. Only one participant was enrolled, so the results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Biosensor algorithm
What this could lead to: If successful, this could lead to more accurate glucose monitoring and better insulin delivery algorithms for people with type 1 diabetes.
What could go wrong: This was a very small, early-stage study with only one participant, so results may not apply to others. The biosensor is still experimental and not yet proven better than existing systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

Hôpital Saint-André

Bordeaux, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.